PCI Biotech Holding ASA (OSTO:PCIBO)
kr 1.8 0 (0%) Market Cap: 48.60 Mil Enterprise Value: 18.54 Mil PE Ratio: 0 PB Ratio: 1.52 GF Score: 29/100

Q3 2019 PCI Biotech Holding ASA Earnings Call Transcript

Nov 27, 2019 / 07:30AM GMT
Release Date Price: kr40 (+8.11%)
Per Walday
PCI Biotech Holding ASA - CEO

Good morning, everyone, and welcome to PCI Biotech's Third Quarter Presentation 2019. My name is Per Walday. I'm the CEO of PCI Biotech, and I have with me also Ronny Skuggedal who is the CFO of PCI Biotech.

So we will start with going through a bit around the background and technology of the company, then moving into the highlights. And after that, going more into details in the 3 different programs before we end up with talking about the outlook.

So to start a bit with the company. So PCI Biotech is developing a platform technology, the platform technology is called Photochemical Internalization. It has been invented here at the Radium Hospital in the building next to where we are today. And we are developing this specific technology in 3 different programs. We call them fimaCHEM, fimaVACC and fimaNAc. It's all based on the same platform technology, but it addresses 3 different areas of unmet medical need.

The first one is to enhance locally the effect of chemotherapeutics that are already approved. And this is the lead program that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot